Innovator U.S. Equity Buffer ETF - March (BATS: BMAR)

Latest news for Innovator U.S. Equity Buffer ETF - March (BATS:BMAR)

The fund invests at least 80% of its net assets in FLexible EXchange Options (FLEX Options) that reference the S&P 500 Price Return Index (S&P 500 Price Index). FLEX Options are exchange-traded options contracts with uniquely customizable terms. Although guaranteed for settlement by the Options Clearing Corporation (the OCC), FLEX Options are still subject to counterparty risk with the OCC and may be less liquid than more traditional exchange-traded options. It is non-diversified.

Innovator US Equity Buffer ETF - March

Innovator U.S. Equity Buffer ETF - March

WIIM

Hut 8 Corp shares are trading higher after the company announced it expanded its partnership with BITMAIN to unveil the next-gen liquid-cooled ASIC miner for Bitcoin mining.

Boeing Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) stock is flying low as the company battles a machinist strike that has forced tens of thousands of workers <a href="https://www.benzinga.com/quote/BA/news">off the job</a>. 
In a bid to cut costs, Boeing <a href="https://www.benzinga.com/markets/equities/24/09/40931613/boeing-enforces-temporary-furloughs-amid-strike-ceo-kelly-ortberg-announces-difficult-steps-like">has furloughed thousands</a> of U.S. employees, executives, and non-essential contractors. CEO Kelly Ortberg confirmed the furloughs in a memo, adding that these steps are necessary to preserve cash amid the ongoing labor disruption.
The strike began after more than 30,000 machinists in Seattle and Oregon rejected Boeing's latest contract offer, with 96% voting to walk off. Despite a 25% raise on the table, workers argued the offer failed to match the skyrocketing cost of living in the Seattle area. Negotiations remain tense, and the union's frustration is mounting.
<h2 class="wp-block-heading">Boeing Chart Suggests Turbulence Ahead</h2>
Boeing's stock price has been unable to lift off amid this chaos. At $155.30, BA is below its five, 20, and 50-day exponential moving averages (EMAs), signaling a strong bearish trend.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="623" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19105209/Screenshot-2024-09-19-at-8.21.18-PM.png" alt="" class="wp-image-556505" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19105209/Screenshot-2024-09-19-at-8.21.18-PM.png 623w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19105209/Screenshot-2024-09-19-at-8.21.18-PM-300x219.png 300w" sizes="(max-width: 623px) 100vw, 623px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091924&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The eight-day simple moving average, at $157.91, and the 20-day SMA, at $164.06, all signal more downside ahead.
Additional dark clouds hover as the 50-day SMA is at $172.00, while the 200-day SMA sits at $192.33, indicating that Boeing's stock is technically bearish across the board.
Read Also: <a href="https://www.benzinga.com/news/24/09/40886979/boeing-stock-continues-to-fall-after-announcing-hiring-freeze-other-cost-cuts-amid-workers-strike">Boeing Stock Continues To Fall After Announcing Hiring Freeze, Other Cost Cuts Amid Workers&#8217; Strike</a>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="623" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19105213/Screenshot-2024-09-19-at-8.21.32-PM.png" alt="" class="wp-image-556506" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19105213/Screenshot-2024-09-19-at-8.21.32-PM.png 623w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19105213/Screenshot-2024-09-19-at-8.21.32-PM-300x219.png 300w" sizes="(max-width: 623px) 100vw, 623px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091924&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The MACD (Moving Average Convergence/Divergence) is a negative 4.85, reinforcing the bearish momentum.
Boeing stock is currently nearing oversold territory, with an RSI of 36.57, indicating the potential for some short-term relief. However, this offers little comfort to investors at the moment.
Even the Bollinger Bands ($150.30 &#8211; $182.72) scream bearish, with Boeing stock trading in the lower band, signaling continued pressure.
As Boeing navigates this turbulence, investors may need to brace for further dips before clear skies return.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40899599/elon-musk-said-spacex-competitors-only-take-up-less-than-we-do-and-they-take-nothing-down-and-they-g">Elon Musk Said SpaceX Competitors Only &#8216;Take Up Less Than We Do, And They Take Nothing Down, And They Get Paid Twice As Much&#8217; — 10 Years Later, Its Rival In Space Boeing Has Frozen Hiring And Is Weighing Furloughs</a></li>
</ul>
Photo: Shutterstock

Technicals

Boeing Braces For Turbulence As Strikes, Furloughs Send Stock Sliding, Bearish Signals Prevail

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics shares are trading higher after the company announced that data from its Nomlabofusp Phase 1 studies and Phase 2 dose exploration will be presented at the annual International Congress for Ataxia Research.

Citigroup analyst James Hardiman maintains Harley-Davidson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) with a Neutral and raises the price target from $37 to $39.

News

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Harley-Davidson, Raises Price Target to $39

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Biotech

Global

General

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

APLT

Applied Therapeutics shares are trading higher after Leerink Partners and Citigroup raised their respective price targets on the stock.

Stifel analyst Jeffrey Stantial reiterates Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Buy and lowers the price target from $259 to $223.

Reiteration

Stifel Reiterates Buy on Vail Resorts, Lowers Price Target to $223

Citigroup analyst Keith Horowitz maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $25 to $26.

Citigroup Maintains Buy on Regions Finl, Raises Price Target to $26

<a href="https://www.sec.gov/newsroom/press-releases/2024-140" title="https://www.sec.gov/newsroom/press-releases/2024-140">https://www.sec.gov/newsroom/press-releases/2024-140</a>

Legal

MQBKY

"SEC Charges Advisory Firm Macquarie Investment Management Business Trust with Fraud; Firm To Pay Nearly $80 Million In Connection With Overvaluing Assets And Engaging In Unlawful Cross Trades" - SEC

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Neutral.

ACET

HC Wainwright & Co. Reiterates Neutral on Adicet Bio

FANH

Fanhua shares are trading lower. The company reported H1 financial results.

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions shares are trading lower. The company reported Q4 financial results.

MoneyHero shares are trading lower. The company reported Q2 financial results.

Citigroup analyst Jason Bazinet maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $110 to $155.

Citigroup Maintains Buy on AppLovin, Raises Price Target to $155

Macquarie analyst Tim Nollen maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Neutral and lowers the price target from $94 to $91.

Macquarie Maintains Neutral on Walt Disney, Lowers Price Target to $91

ELWS

Earlyworks shares are trading higher after the company announced a business alliance agreement with CIACA DIGITAL to support the expansion of Web3 businesses.

Stifel analyst Simon Yarmak maintains SITE Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) with a Buy and raises the price target from $65 to $65.25.

SITC

Stifel Maintains Buy on SITE Centers, Raises Price Target to $65.25

Citigroup analyst Keith Horowitz maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Neutral and raises the price target from $65 to $70.

Citigroup Maintains Neutral on Bank of New York Mellon, Raises Price Target to $70

KSPI

Joint Stock Company Kaspi.Kz shares are trading lower after Culper Research issued a report on the company.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) with a Buy and maintains $5 price target.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Innovator U.S. Equity Buffer ETF - March

News

Latest news for Innovator U.S. Equity Buffer ETF - March (BATS:BMAR)